NASH is part of a multi-system disorder
Prof Sanyal, USA, reminds us that NAFLD is the most common liver disease and reviews the comorbidities associated with NAFLD, and particularly the association with cardiovascular disease. He makes the point that NASH is part of a multi-system disorder and also presents the key concepts related to management, including risk stratification. An important learning is not to miss opportunities of early identification of patients at risks to improve the patients’ journey.
Read MoreFrom number-one liver disease to multi-system disease: NASH, a major unmet clinical need
In this opening talk of the 1st PanNASH webinar, Prof. Sven Francque (Belgium), one of the PanNASH editors, explains how NASH, the number-one liver disease, is part of a multisystem disease. He also sheds light on the etiology of this disease, its epidemiology, symptoms and consequences.
Read MoreNon-alcoholic fatty liver disease (NAFLD): a multisystem disease – part 2
It is well known that NAFLD and T2DM occur commonly together. Prof Byrne (Southampton, UK) discusses the latest findings showing that NAFLD is an independent risk factor for cardiovascular events. The aetiology of increased risk of CVD is complex but the atherogenic dyslipidaemia is important. Genotypes can increase severity of liver disease and diabetes, yet attenuate risk of CVD.
Read MoreNon-alcoholic fatty liver disease (NAFLD): a multisystem disease – part 1
Prof. Rautou, France, discusses a critical component of the diagnosis and management of NASH: biomarkers. There are 2 aspects: fibrosis and diagnosis. Diagnosis is a field of investigations. Microvesicles could play a role.
Read MoreManagement of non-alcoholic steatohepatitis (NASH): a multiorgan disease driven by insulin resistance, obesity and T2D
Prof. Rautou, France, discusses a critical component of the diagnosis and management of NASH: biomarkers. There are 2 aspects: fibrosis and diagnosis. Diagnosis is a field of investigations. Microvesicles could play a role.
Read MorePhase 3 development in the field of non-alcoholic steatohepatitis (NASH)
Prof. Rautou, France, discusses a critical component of the diagnosis and management of NASH: biomarkers. There are 2 aspects: fibrosis and diagnosis. Diagnosis is a field of investigations. Microvesicles could play a role.
Read More
NASH treatment: State of the art in 2020
NASH treatment: State of the art in 2020
Read MoreNAFLD and states of insulin resistance
Insulin resistance is tightly linked to NAFLD, particularly in those with Type 2 Diabetes.
In this video, Prof. Michael Roden, Germany discusses this link, its origins that can inherited or acquired. He also sheds light on the consequences of insulin resistance.
The prevalence, risks and costs of NASH
NASH is associated with cardiovascular diseases and cardiovascular mortality. Prof Rosano, UK discusses the prevalence, risks and economic costs of NAFLD and NASH. He sheds lights on the risk of obesity that induces many changes. He also reviews countries with higher prevalence, age characteristics and the incidence and progression of the disease
Read MoreLipids effects of PPARs by Prof. F. Sacks
Prof Sacks, USA summarises what we know about the PPARs lipid effects. If the strongest evidence is with PPAR-alpha agonists for which the main lipid effect is lowering triglycerids, the are interesting information to discuss about PPAR-delta (Seladelpar).
Read More